Promising of Multidrug-resistant Tuberculosis Screening among New Tuberculosis Patients in China | Zendy

Hui Zhang | Zendy; Zhongwei Jia | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Promising of Multidrug-resistant Tuberculosis Screening among New Tuberculosis Patients in China

Author(s) -

Hui Zhang,

Zhongwei Jia

Publication year - 2017

Publication title -

chinese medical journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.537

H-Index - 63

eISSN - 2542-5641

pISSN - 0366-6999

DOI - 10.4103/0366-6999.213433

Subject(s) - medicine , tuberculosis , genexpert mtb/rif , extensively drug resistant tuberculosis , multi drug resistant tuberculosis , rifampicin , multiple drug resistance , drug resistance , environmental health , pediatrics , mycobacterium tuberculosis , pathology , microbiology and biotechnology , biology

Peng et al.[1] reported that the MDR‐TB burden among the new tuberculosis (TB) patients accounted for more than 1/4th of all multidrug‐resistant TB (MDR‐TB) cases in the past 5 years in Zhejiang province, although the identified rate of MDR‐TB among 9830 new TB cases was only 2.0%. Drug‐resistant TB, especially MDR‐TB, is a major threat to the control of TB worldwide. However, due to high cost and limited budget, screening on MDR‐TB has not been implemented among all TB cases by now.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research